It has the effects of anti-platelet aggregation, dilating arterioles, improving microcirculation, activating blood circulation and removing blood stasis, and has the effect of disaggregating aggregated platelets

Extract from the above information

It has high antibacterial activity against common aerobic Gram-positive bacteria, such as Staphylococcus aureus (including those resistant to penicillin G), Staphylococcus epidermidis, beta-hemolytic Streptococcus, viridans Streptococcus and Streptococcus pneumoniae. It has good antibacterial effect on anaerobic bacteria, including Clostridium diphtheriae, and Clostridium perfringens. It has no activity against Gram-negative bacteria such as enterococci, meningococci, Neisseria gonorrhoeae, and Haemophilus influenzae, as well as fungi. There is no cross-resistance with penicillin, chloramphenicol, cephalosporins and tetracyclines, and there is partial cross-resistance with macrolides. It acts on the 50S subunit of the ribosome of sensitive bacteria, preventing the extension of the peptide chain, thereby inhibiting the protein synthesis of bacterial cells. It is generally an antibacterial agent, but at high concentrations, it also has a bactericidal effect on certain bacteria.

No specific pharmacological effects mentioned

This product is a nitroimidazole derivative that can inhibit the redox reaction of amoeba and break the nitrogen chain of the protozoa. In vitro tests have shown that when the drug concentration is 1-2 mg/L, the histolytica amoeba can undergo morphological changes in 6-20 hours and all are killed within 24 hours. When the concentration is 0.2 mg/L, the histolytica amoeba can be killed within 72 hours. This product has a strong effect of killing trichomonas, and its mechanism is unknown. Metronidazole has a killing effect on anaerobic microorganisms, and the metabolites generated when it is reduced in the human body also have anti-anaerobic effects, inhibiting the synthesis of bacterial deoxyribonucleic acid, thereby interfering with the growth and reproduction of bacteria, and ultimately causing bacterial death. Metronidazole is carcinogenic to some animals.

This product is a nitroimidazole derivative that can inhibit the redox reaction of amoeba and break the nitrogen chain of the protozoa. In vitro tests have shown that when the drug concentration is 1-2 mg/L, the histolytica can undergo morphological changes in 6-20 hours and all are killed within 24 hours. When the concentration is 0.2 mg/L, the histolytica can be killed within 72 hours. This product has a strong effect of killing trichomonas, and its mechanism is unknown. Metronidazole has a killing effect on anaerobic microorganisms, and the metabolites generated when it is reduced in the human body also have anti-anaerobic effects, inhibiting the synthesis of bacterial deoxyribonucleic acid, thereby interfering with the growth and reproduction of bacteria, and ultimately causing bacterial death. Metronidazole is carcinogenic to some animals.